Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients: Clonal evolution and impact of IFN treatment

S. Hasan; B. Cassinat; N. Droin; J. P. Le Couedic; F. Favale; B. Monte-Mor; C. Lacout; M. Fontenay; C. Dosquet; C. Chomienne; E. Solary; J. L. Villeval; N. Casadevall; J. J. Kiladjian; W. Vainchenker; I. Plo

doi:10.1038/leu.2013.303

Use of the 46/1 haplotype to model JAK2 ^V617F clonal architecture in PV patients: Clonal evolution and impact of IFN treatment

S. Hasan, B. Cassinat, N. Droin, J. P. Le Couedic, F. Favale, B. Monte-Mor, C. Lacout, M. Fontenay, C. Dosquet, C. Chomienne, E. Solary, J. L. Villeval, N. Casadevall, J. J. Kiladjian, W. Vainchenker, I. Plo

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

13 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	460-463
Nombre de pages	4
journal	Leukemia
Volume	28
Numéro de publication	2
Les DOIs	https://doi.org/10.1038/leu.2013.303
état	Publié - 1 févr. 2014

Accès au document

10.1038/leu.2013.303

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Hasan, S., Cassinat, B., Droin, N., Le Couedic, J. P., Favale, F., Monte-Mor, B., Lacout, C., Fontenay, M., Dosquet, C., Chomienne, C., Solary, E., Villeval, J. L., Casadevall, N., Kiladjian, J. J., Vainchenker, W., & Plo, I. (2014). Use of the 46/1 haplotype to model JAK2 ^V617F clonal architecture in PV patients: Clonal evolution and impact of IFN treatment. Leukemia, 28(2), 460-463. https://doi.org/10.1038/leu.2013.303

@article{1fc8837a61b54bce8b57580356bb7af3,

title = "Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients: Clonal evolution and impact of IFN treatment",

author = "S. Hasan and B. Cassinat and N. Droin and {Le Couedic}, {J. P.} and F. Favale and B. Monte-Mor and C. Lacout and M. Fontenay and C. Dosquet and C. Chomienne and E. Solary and Villeval, {J. L.} and N. Casadevall and Kiladjian, {J. J.} and W. Vainchenker and I. Plo",

note = "Funding Information: We are grateful to Franc¸oise Wendling and Caroline Marty for improving the manuscript. We thank Yann Lecluse and Philippe Rameau from the Imaging Platform for their help in cytometry analysis and cell sorting, and Yannis Dufourd and Noemie Pata-Merci from the Genomic Platform for NGS analysis. This work was supported by grants from the Agence Nationale de la Recherche (Epigenome 2010, Thrombocytosis 2011), the Foundation ARC (Association pour la Recherche contre le Cancer, IP), the Ligue Nationale contre le Cancer (WV, ES) and the {\textquoteleft}{\textquoteleft}Investissements d{\textquoteright}avenir{\textquoteright}{\textquoteright} programme (Labex GR-Ex; IP, WV). HS, FF and BM-M were supported by fellowships from la Ligue Nationale Contre le Cancer, the Foundation ARC, and the Fondation pour la Recherche M{\'e}dicale, respectively. WV is a recipient of a research fellowship from Gustave Roussy and INSERM (contrat d{\textquoteright}interface). IP is supported by grants from Foundation ARC (projet libre 2012).",

year = "2014",

month = feb,

day = "1",

doi = "10.1038/leu.2013.303",

language = "English",

volume = "28",

pages = "460--463",

journal = "Leukemia",

issn = "0887-6924",

number = "2",

}

Hasan, S, Cassinat, B, Droin, N, Le Couedic, JP, Favale, F, Monte-Mor, B, Lacout, C, Fontenay, M, Dosquet, C, Chomienne, C, Solary, E, Villeval, JL, Casadevall, N, Kiladjian, JJ, Vainchenker, W & Plo, I 2014, 'Use of the 46/1 haplotype to model JAK2 ^V617F clonal architecture in PV patients: Clonal evolution and impact of IFN treatment', Leukemia, VOL. 28, Numéro 2, p. 460-463. https://doi.org/10.1038/leu.2013.303

TY - JOUR

T1 - Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients

T2 - Clonal evolution and impact of IFN treatment

AU - Hasan, S.

AU - Cassinat, B.

AU - Droin, N.

AU - Le Couedic, J. P.

AU - Favale, F.

AU - Monte-Mor, B.

AU - Lacout, C.

AU - Fontenay, M.

AU - Dosquet, C.

AU - Chomienne, C.

AU - Solary, E.

AU - Villeval, J. L.

AU - Casadevall, N.

AU - Kiladjian, J. J.

AU - Vainchenker, W.

AU - Plo, I.

N1 - Funding Information: We are grateful to Franc¸oise Wendling and Caroline Marty for improving the manuscript. We thank Yann Lecluse and Philippe Rameau from the Imaging Platform for their help in cytometry analysis and cell sorting, and Yannis Dufourd and Noemie Pata-Merci from the Genomic Platform for NGS analysis. This work was supported by grants from the Agence Nationale de la Recherche (Epigenome 2010, Thrombocytosis 2011), the Foundation ARC (Association pour la Recherche contre le Cancer, IP), the Ligue Nationale contre le Cancer (WV, ES) and the ‘‘Investissements d’avenir’’ programme (Labex GR-Ex; IP, WV). HS, FF and BM-M were supported by fellowships from la Ligue Nationale Contre le Cancer, the Foundation ARC, and the Fondation pour la Recherche Médicale, respectively. WV is a recipient of a research fellowship from Gustave Roussy and INSERM (contrat d’interface). IP is supported by grants from Foundation ARC (projet libre 2012).

PY - 2014/2/1

Y1 - 2014/2/1

UR - http://www.scopus.com/inward/record.url?scp=84893786554&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.303

DO - 10.1038/leu.2013.303

M3 - Letter

C2 - 24150219

AN - SCOPUS:84893786554

SN - 0887-6924

VL - 28

SP - 460

EP - 463

JO - Leukemia

JF - Leukemia

IS - 2

ER -